DEF: Haemonetics Corporation Announces Notice of 2025 Annual Meeting of Shareholders

Haemonetics Corporation announces its 2025 Annual Meeting of Shareholders to be held on July 24, 2025, with proposals including the election of directors, executive compensation, and ratification of the accounting firm.

Summary

• The 2025 Annual Meeting of Shareholders will be held on July 24, 2025, at 8:00 A.M. Eastern Time in Boston, Massachusetts.
• Shareholders of record as of May 27, 2025, are eligible to vote.
• The meeting agenda includes the election of nine director nominees to one-year terms, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• Haemonetics' fiscal 2025 highlights include revenue of $1.361 billion, adjusted EPS of $4.57, free cash flow of $144.6 million, and an adjusted operating margin of 24.0%.
• The company achieved significant milestones in its business evolution and drove improved profitability and growth momentum as it navigated external market challenges.
• The Board recommends voting FOR each of the director nominees, FOR the advisory vote on executive compensation, and FOR the ratification of Ernst & Young LLP.

Sentiment

Score: 7

Explanation: The document presents a mix of positive financial results and strategic achievements alongside challenges and market uncertainties. The overall tone is cautiously optimistic, focusing on long-term value creation.

Positives

• Haemonetics achieved revenue of $1.361 billion in fiscal 2025, a 4.0% reported increase and a 1.4% organic increase from the prior fiscal year.
• Adjusted EPS increased by 15.4% to $4.57 in fiscal 2025.
• Free cash flow increased by 23.3% to $144.6 million in fiscal 2025.
• Adjusted operating margin increased by 290 basis points to 24.0% in fiscal 2025.
• The company launched new products, including the VASCADE MVP XL mid-bore venous closure device and the TEG 6s hemostasis analyzer system's global hemostasis-heparinized neutralization assay cartridge.
• Haemonetics acquired Advanced Cooling Therapy, Inc. (d/b/a Attune Medical) to complement its Interventional Technologies portfolio.
• The company divested its Whole Blood product line to better align resources toward higher margin, higher growth opportunities.
• Haemonetics completed $225 million in share repurchases to address the dilutive impact of equity grants.

Negatives

• The company faced external market challenges, including rapidly evolving trends in electrophysiology, a temporary pullback in plasma collections, and difficult market conditions in China.
• Plasma organic revenue declined 6% due to a temporary pullback in collection volumes and the planned transition of CSL Plasma.
• The company's share price performance declined in fiscal 2025 as it navigated external market challenges and macroeconomic uncertainties.
• Hospital business unit revenue achievement against fiscal 2025 targets was below threshold.

Risks

• The company navigated external market challenges, including rapidly evolving trends in electrophysiology, a temporary pullback in plasma collections, difficult market conditions in China and other macroeconomic uncertainties.
• Forward-looking statements are subject to risks and uncertainties, as detailed in the company's Annual Report on Form 10-K.

Future Outlook

Haemonetics is confident in its foundation to deliver sustained, long-term value to customers and shareholders in fiscal 2026 and beyond.

Management Comments

• "We challenge ourselves every day to drive greater possibilities and meaningfully advance healthcare."
• "We challenge ourselves to think big and make new possibilities a reality, so that our customers can make it matter for patients, every single day."

Industry Context

Haemonetics operates in the global medical technology industry, providing solutions for commercial plasma, hospitals, and blood centers. The company's performance is influenced by trends in these sectors, including the demand for plasma, hospital technologies, and blood components.

Comparison to Industry Standards

• Haemonetics benchmarks its executive compensation against a peer group including Avanos Medical, Bruker Corporation, Insulet Corporation, Merit Medical Systems, Azenta, CONMED Corporation, Integra LifeSciences, QuidelOrtho Corporation, Bio-Rad Laboratories, Globus Medical, LivaNova PLC, Revvity, Bio-Techne Corp, ICU Medical, Masimo Corporation and Teleflex incorporated.
• The company's revenue and market capitalization are compared to the 50th percentile of its peer group to ensure competitive positioning.
• Haemonetics targets transformational growth, diversification, and sustainability in its business, aligning with industry trends.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company's performance and governance practices directly impact shareholder value and returns.
• Employees: Compensation programs, benefits, and corporate responsibility initiatives affect employee morale and engagement.
• Customers: The company's innovative solutions aim to improve the quality, effectiveness, and efficiency of healthcare for customers.
• Communities: Corporate responsibility programs support the long-term health and success of the communities in which the company operates.

Next Steps

• Shareholders are encouraged to vote via the Internet, telephone, or mail.
• The Board will consider the outcome of the advisory vote on executive compensation when making future decisions.
• The company expects to publish its next Corporate Responsibility report in summer 2025.

Key Dates

Recommendation

Keywords

Haemonetics, Annual Meeting, Shareholders, Proxy Statement, Executive Compensation, Director Election, Ernst & Young, Financial Performance, Plasma, Hospital, Blood Center, Corporate Governance